Looking past DepoCyt...
To directly answer your question, naloxone is a commonly-used opiate antagonist which works IV or IM. It is available in generic formulations and is inexpensive (about $11 for a dose). This medication is kept at most nursing stations in hospitals. It is what we use when we guess wrong with our analgesia. This is no obstacle at all.
Clearly, a lot remains to be proven about DepoMorph. However, I read one recent analyst's report on DEPO earlier this week who, surprisingly, thought DEPO probably would NOT partner DepoMorph because he thought the clinical trials would be relatively inexpensive, in contrast to DepoAmikacin, for example.
I tend to share Baird's sentiments about the "take the money and run" strategy. My situation is a little unusual, in that I own a day's worth of trading volume. It happens that on December 19, the trading volume will probably exceed 1 million shares. It is a rare opportunity to lighten my very aggressive position without working against myself.
But, if you read the NSTA thread, Scott had a nightmarish experience with NSTA. I invited him to take a look a DEPO because it offers him a chance to record some short-term capital gains in time to offset his short-term capital losses from NSTA in this tax year. His circumstance is different from mine. I already need to do unprecedented (for me) charitable contributions this year, even before any DEPO effect. My best tax strategy would be to reassess the situation in 1998. So, I am still open-minded.
Bottom line: personal circumstances and investment time-frames will probably dictate what people do after the 18th, more than any omniscient prediction about how little or great or brief or long the post-approval selloff will be.
Best Regards, and its good to hear from Baird again,
Tom D |
